NewsClick

NewsClick
  • हिन्दी
  • Politics
  • Economy
  • Covid-19
  • Science
  • Culture
  • India
  • International
  • Sports
  • Articles
  • Videos
search
menu

INTERACTIVE ELECTION MAPS

image/svg+xml
  • All Articles
  • Newsclick Articles
  • All Videos
  • Newsclick Videos
  • हिन्दी
  • Politics
  • Economy
  • Science
  • Culture
  • India
  • Sports
  • International
  • Africa
  • Latin America
  • Palestine
  • Nepal
  • Pakistan
  • Sri Lanka
  • US
  • West Asia
About us
Subscribe
Follow us Facebook - Newsclick Twitter - Newsclick RSS - Newsclick
close menu
×
For latest updates on nCOVID-19 around the world visit our INTERACTIVE COVID MAP
Health
Science
International

Can Antiviral, Antimalarial Drugs Cure COVID-19? WHO Launches Mega Trial

Instead of finding new medication for the infection, which would take months or years to develop, scientists and medical practitioners are looking at the relevance and efficacy of the already available ones, which can be repurposed.
Sandipan Talukdar
25 Mar 2020
WHO launches SOLIDARITY programme to find medicine for Coronavirus.

Representational image. | Image Courtesy: NDTV

Amid the panic following the COVID-19 pandemic, some reports about combinations of some antiviral and antimalarial drugs being used to cure the disease are making rounds. Even US President Donald Trump said that chloroquine may cure COVID-19. But scientific and clinical validation before using it on patients is still awaited. In this context, the World Health Organization [WHO] has announced recently that it would conduct a large global trial, named SOLIDARITY to look for the right treatment.

In this unprecedented effort, a robust collection of scientific data is the main aim on part of the WHO and that too amidst the pandemic. The study is planned in a simple manner so that a hospital, which has been overwhelmed by patients, can also take part in it. It aims to include many thousand patients and dozens of countries.

About 15% of the patients suffering from COVID-19 fall under the ‘severe’ category and need intensive hospital care. As a result, hospitals are overwhelmed in no time and doctors urgently need to have some medication to treat it. Instead of finding new medication for the infection, which would take months or years to develop, scientists and medical practitioners are looking at the relevance and efficacy of the already available ones, which can be repurposed. They are also looking at the unapproved drugs that proved to have been fruitful in treating the other two coronavirus infections: SARS and MERS.

Scientists have suggested many existing compounds as probable COVID-19 drugs, and WHO has zeroed down to four such compounds to be tested globally in its SOLIDARITY programme: Remdesivir, an experimental antiviral compound, Chloroquine and Hydroxychloroquine, the antimalarial drugs, Lopinavir and Ritonavir, the combination of two anti-HIV drugs and the same combination plus Interferon-Beta, an immune system messenger that can destroy viruses. Some data on the use of these compounds have already emerged: the HIV combination reported to have failed in a small study in China. But, a large trial with a large variety of patients is required.

Enrolling for SOLIDARITY will be easy—the data of COVID-19 patients, who are deemed eligible by the physicians, will be collected by a WHO website. This will also include underlying conditions that could change the course of the disease such as diabetes or HIV infection. The participant will have to sign a consent form which would be scanned and sent to the WHO. The consulting physician will have to state which drugs are available at his or her hospital and after that, the website will randomly prescribe to the patient one of the available drugs.

Ana Maria Henao Restrepo, a medical officer at WHO’s Department of Immunization Vaccines and Biologicals, said— “After that, no more measurements or documentation are required. Physicians will record the day the patient left the hospital or died, the duration of the hospital stay, and whether the patient required oxygen or ventilation, that’s all.”

Let’s have a look at the treatments that SOLIDARITY programme will test:

Remdesivir

This compound was originally developed to fight the Ebola virus, along with some other related viruses. Remdesivir functions to inhibit viral replication. It does so by inhibiting the vital enzyme called RNA dependent RNA polymerase. This enzyme augments the viral replication.

Remdesivir was tested last year to treat Ebola in Congo, but turned out to be ineffective. On the other hand, a 2017 study conducted at the University of North Carolina, Chapel Hill, found that Remdesivir can inhibit other coronaviruses that cause SARS and MERS.

Remdisivir was also given to the first COVID-19 patients in the US and NEJM (New England Journal of Medicine) reported that the condition of the patients improved on the next day. Also, a Californian patient--who had slim chances of survival--has reportedly recovered after administering Remdisivir.

Although a few cases of recovery do not imply that a drug is safe and effective, SOLIDARITY has included the drug in its list. This probably has the best potential for clinical use.

Chloroquine and Hydroxychloroquine

The classical antimalarial compounds are now making headlines as a possible remedy for COVID-19. In Indian markets, this medicine has already gone out of stock. But the available data for its use is very weak. The drugs function by decreasing the acidity of the endosomes, which are compartments inside the cells that are used to ingest outside material and are entry points of the SARS-CoV-2. It uses its spike proteins to cling onto the receptors present on the cell surface. Endosomes remain inside the cells.

Cell culture studies showed that chloroquine presents some activities against SARS-CoV-2, but the dose required is very high and toxicity remains a concern.

France researchers have showed that hydroxychloroquine, when administered to the COVID patients, significantly reduced the viral load in the nasal swabs. But it was not a randomised control trial and also has not reported clinical outcomes such as death.

Chinese researchers also reported treating more than 100 patients with chloroquine successfully, but the data in this regard have not been published.

Ritonavir/Lopinavir

This combination is used to treat the HIV infection. Lopinavir inhibits the HIV protease enzyme, a key enzyme that cleaves the long protein chain into constituent peptides during the assembly of new viruses. Lopinavir is quickly degraded by our own proteases, the enzymes that cleave proteins. For this reason, Lopinavir is combined with Ritonavir, a protease inhibitor.

This combination is believed to inhibit proteases of other viruses as well, including the coronaviruses. But the trial for COVID-19 does not give encouraging results. A Chinese trial published in NEJM says that the combination does not show significant improvement in COVID-19 patients.

Ritonavir/Lopinavir and Interferon-beta

Interferon beta is a molecule that is involved in regulating inflammation in the body. The combination of Ritonavir/Lopinavir antiviral with interferon beta will be tested by SOLIDARITY.

 A combination of the three drugs is now tested in Saudi Arabia to treat MERS patients in the first randomised controlled trial.

So far, there is no ready remedy for COVID-19. While developing a vaccine is surely going to take a long time, a remedy out of already available compounds will certainly help deal with the pandemic. 

Get the latest reports & analysis with people's perspective on Protests, movements & deep analytical videos, discussions of the current affairs in your Telegram app. Subscribe to NewsClick's Telegram channel & get Real-Time updates on stories, as they get published on our website.
WHO’s SOLIDARITY programme
solidarity
Chloroquine
remdesivir
Ritonavir
Lopinavir
Interferon Beta
Related Stories
Most Clinical Trials for COVID-19

Most Clinical Trials for COVID-19 Are Disorganised, Says Report

Break Gilead’s Patent Since US has Bought all Stock of Remdesivir

Venezuela’s Borderlands Have Been Assaulted by COVID-19

Venezuela’s Borderlands Have Been Assaulted by COVID-19

Public Health and Private Profits Under COVID-19 Pandemic

Public Health and Private Profits Under COVID-19 Pandemic

How Discovering the Structure of SARS-CoV-2 Makes Antiviral Drug Design Possible

COVID-19

In Times of Pandemic, Movements and Organisations Defend the Right to a Dignified Life

FDA Approves Anti-Malarial Drug Chloroquine to Treat Coronavirus: Trump

FDA Approves Anti-Malarial Drug Chloroquine to Treat Coronavirus: Trump

Digital illustration of ncovid-2019 (noval coronavirus 2019)

World at a Tipping Point as COVID-19 Breach 100,000 Victims

NUMSA

NUMSA Meet will Decide Further Course of Action for South Africa’s Labour Disputes

Zambia Socialist Party

“For the Humblest of the Zambian People, There is No Other Alternative to Socialism”

Share on FacebookShare on TwitterShare on WhatsAppShare via EmailShare on RedditShare on KindlePrint
Share
Share on FacebookShare on TwitterShare on WhatsAppShare via EmailShare on RedditShare on KindlePrint
Share

Related Stories

Sandipan Talukdar

COVID-19: Study Claims Chemotherapy Drug could be Repurposed for Treatment, Caveats Remain

01 January 2021
A recent paper published in the journal
Brasil de Fato

MST Promises to Replace “every brick” Torn Down in Eviction of Landless Families

20 August 2020
“They ran over my coffee plants with a tractor. They ran over my orchard. They burned my banana plants.
Peoples Dispatch

Noam Chomsky and Vijay Prashad Denounce Eviction of Families from Quilombo Campo Grande

17 August 2020
The eviction of 450 families from the camp of the Landless Rural Workers’ Movement (NST) called Quilombo Campo Grande has generated widespread

Pagination

  • Next page ››

More

  • MP: With Prices above Rs 100 even Petrol Pump Owners look to Uttar Pradesh for a Refill

    MP: With Prices above Rs 100 even Petrol Pump Owners look to Uttar Pradesh for a Refill

  • Is Centre Targeting Kerala Infrastructure Investment Fund Board Through ED?

    Is Centre Targeting Kerala Infrastructure Investment Fund Board Through ED?

  • UP Kisan Sabha to Hold 'Maha Padyatra' to Delhi Border, 'Expose' Govt Lies about Farm Laws

    UP Kisan Sabha to Hold 'Maha Padyatra' to Delhi Border, 'Expose' Govt Lies about Farm Laws

  • Bengal Elections: The Divided Colours of Tollywood

    Bengal Elections: The Divided Colours of Tollywood

  • Load More
Subscribe
connect with
about